Skin treatments developer Syntopix has signed an exclusive agreement with what it calls a “world leader in marketing home, health and personal care brands”.
The agreement gives the client right of first refusal for the development and commercialisation of one of Syntopix’s compounds.
At 62p a share, Syntopix is valued at £6.64m. The share price has fallen by nearly one-quarter over the past year.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.